Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with additional funding from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research and development, and talent recruitment.
Company Overview and Innovation
Founded in 2021, Xinrui Medtech specializes in developing innovative cardiovascular devices. The company boasts polymer valve core materials that have been verified by a third party, with performance comparable to that of US firm Foldax’s LifePolymer. This innovation positions Xinrui Medtech at the forefront of cardiovascular device development.
Significance of the Funding
The pre-Series A financing round is a significant milestone for Xinrui Medtech, providing the necessary resources to accelerate its growth and expand its product offerings. By investing in clinical studies and R&D, the company aims to enhance its technological capabilities and bring more effective and reliable cardiovascular solutions to the market.-Fineline Info & Tech
